Lowest Price Guaranteed
Slides
220
Last Updated
August 2026
View Count
15032
The smart inhalers market size is valued at USD 1.53 billion in 2024 and is expected to reach USD 5.84 billion by 2035, representing a CAGR of 12.95% during the forecast period 2024-2035.
 |
To learn more about this report, request a free sample copy
With the rise in air pollution and poor lifestyle habits (active and passive smoking), the prevalence of respiratory diseases (including asthma and chronic obstructive pulmonary disease) is increasing at an alarming rate across the globe. The treatment and management of such disorders require inhaled therapy in order to ensure that the therapeutic drug reaches the lungs in an efficient manner. The conventional inhalers were associated with several technical complexities, such as high dose loading, breathing management and poor inhalation techniques. These technical complexities impacted the dosing which further reduced the patient compliance and medication adherence. As a result, over the years, several pharmaceutical players have been focusing on the development of smart inhalers (a type of connected drug delivery devices) that are easy to use, offer precise dosage and timely intervention, thereby, leading to better health outcomes. Smart inhaler is a form of medical device integrated with advanced technology that allows the patients to monitor the dosage (along with dosage time) and inhalation inflow. This supports them in taking the correct dosage for disease management.
Notably, these smart inhalers feature feedback software that provides personalized feedback to the patients and healthcare professionals, in order to make informed treatment decisions. Interestingly, in June 2024, Aseptika launched PUFFClicker3, an advanced smart inhaler dose tracker which is compatible with both dry powder inhaler and pressurized metered dose inhaler (MDI). These ongoing developments and pilot studies have catered the attention of industry players to drive innovation and expand their infrastructure to support the ongoing demand for smart inhalers (also known as connected inhalers). In an NHS-funded study (that begun recruitment in early 2024), close to 300 children (at high-risk of asthma) will receive Hailie digital inhaler (developed by Adherium) in order to examine the effect on asthma prophylaxis. As stated by Dr Erol Gaillard (University Hospitals, Leicester NHS Trust) “This study represents a huge joint effort from NHS, the university, charity and the MedTech industry to demonstrate how devices like Hailie can help to better control asthma and keep children out of hospital.” Driven by the ongoing efforts by industry and non-industry stakeholders, we believe that the market for smart inhalers will grow at a steady pace during the forecast period, making this market investible for the long term.
The market study report features in-depth analysis of the key industry leaders who are presently active across various segments of the growing industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | USD 5.84 Billion | |
| Market CAGR | 12.95% | |
| Type of Product |
|
|
| Types of Disease Indication |
|
|
| Route of Administration |
|
|
| Type of Distribution Channel |
|
|
| Key Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of smart inhalers market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period. Additionally, the market report features the likely distribution by product type (dry powder inhaler) and metered dose inhaler), by disease indication (asthma and chronic obstructive pulmonary disease), route of administration (orally inhaled and intranasal), distribution channel (hospital pharmacies, retail pharmacies and online channels), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), and key players. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the smart inhaler industry growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market research report are in USD, unless otherwise specified.
Based on the product type, the global smart inhalers market is segmented into dry powder inhaler and metered dose inhaler. According to our projection, metered dose inhaler segment occupies the highest share (close to 65%) of the overall market. MDI is highly efficient to use and largely adapted for asthma and COPD treatment. Moreover, the metered dose inhaler can be integrated with smart technology for dosage adherence tracking by patients. Considering the ease of administration and smart sensors compatibility, various players are leveraging robust partnerships with pharmaceutical companies to enhance the production of metered dose inhalers. However, in the long run, dry power inhaler market segment will show a lucrative growth potential and is anticipated to grow at a higher CAGR during the forecast period. This can be attributed to the increasing demand for personalized medicine with improved delivery efficiency. Dry powered based inhalers can be tailored to meet patient’s requirement, making them ideal choice for patients with respiratory diseases.
Based on the disease indication, the global market is segmented into asthma and chronic obstructive pulmonary disease (COPD). According to our smart inhalers market analysis, COPD accounts for the highest share of the market. It is amongst the most prevalent non-infectious lung disease affecting population worldwide. The growing incidence of COPD such as emphysema and chronic bronchitis has surged the demand for smart inhalers, which contributed to the growth of this segment during the forecast period. However, asthma segment will show lucrative growth potential and is likely to grow at a higher CAGR during the forecast period. This can be attributed to the high demand for smart inhalers by patients with asthma globally for managing pulmonary disease.
Based on the route of administration, the global market is segmented into orally inhaled and intranasal routes. Currently, orally inhaled route accounts for the highest smart inhalers market share owing to the ease of usage in managing chronic respiratory diseases such as asthma. Furthermore, orally inhaled based smart inhalers have been adopted specifically by aged patients which has further contributed to the overall growth of the market. However, in the long run, intranasal inhalers will show a substantial growth potential driven by the increasing preferences of non-invasive drug delivery methods and continuous innovation for the development of digital technology-based intranasal inhalers.
Based on the distribution channels, the smart inhalers market forecast generates revenues through hospital pharmacies, retail pharmacies, and online channel. According to our projection, currently hospital pharmacies occupy the highest share (nearly 45%) of the market owing to flexibility, convenience and comfort of purchasing smart inhalers in the healthcare settings for hospitalized patients. Furthermore, there is an increase in the number of hospitalized patients with chronic respiratory diseases who are the primary user of smart inhalers. Driven by the growing trend towards online purchasing of medicine, online channel is expected to grow at a substantial CAGR during the forecast period. Furthermore, Online purchasing offers wider availability of products at competitive prices, making it a preferable option for ordering smart inhalers online. Furthermore, the integration of digital health platform has significantly improved prescription management, contributing to the overall growth of online channels.
Based on the geographical regions, the global market is distributed into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projection, currently North America accounts for the largest smart inhalers market share (~45%). This dominance is due to the growing prevalence of asthma and other COPD cases in the region. Furthermore, the higher adoption rate of smart medical devices for the management of respiratory diseases in North America region and developed infrastructure have contributed to the overall growth of market in this region. As per our market research, Asia-Pacific market has shown lucrative growth potential owing to the growing geriatric population with respiratory diseases, developing healthcare infrastructure and increasing government initiatives to raise awareness about asthma.
The “Global Smart Inhalers Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study on current market landscape, market size, market share, market growth, market forecast, market outlook and future opportunities of the radiotherapy market. In addition, it features an elaborate discussion on the likely future opportunity associated with this market during the forecast period.
The global market landscape of smart inhalers seems highly competitive, featuring the presence of various industry players across different geographies. These players are actively enrolling in industry research and development activities for the development of smart inhalers technologies with advanced features. In order to strengthen their product portfolio and drive innovative, the key industry okayers who are presently active in this domain are focusing on acquisition, collaborations, and partnerships. Moreover, the key players are focusing on reaching a wider customer base by strengthening their product portfolio for respiratory disorders. It is important to highlight here that the increasing adoption of smart medical devices, several players are investing in the growing market and actively participating in promotions to create awareness about respiratory diseases and significances of smart inhalers in managing diseases. In September 2024, Aptar Pharma entered into a partnership with PULMOTREE in order to advance the development and promotion of Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform.
Some of the potential drivers that are propelling the market include the growing incidence of chronic respiratory diseases across the globe and increasing awareness about preventive care. It is important to highlight here that as per the report of World Health Organization, Chronic obstructive pulmonary disease (COPD) is the third major cause of death globally. Thus, growing concern of chronic respiratory diseases across the globe has underscored the requirement of smart systems for nasal drug delivery that help to deliver accurate dosage for disease management. Furthermore, the increasing awareness about the significances of preventive care among patients with respiratory disease is expected to boost the adoption of smart inhalers, which is further expected to be the key driver of this market.
Some of the potential challenges that may hinder the market growth during the forecast period include high cost of smart inhalers and presence of manual inhalers. It is important to highlight here that the integration of advanced connectivity features and technologies in smart inhalers may enhance the overall cost. This high cost may limit the adoption of smart inhalers on a large scale specifically due to affordability concerns in low disposable income countries. As a result, big pharmaceutical companies, such as GSK have announced their plans to cap out-of-pocket costs (with effective from January 2025) for its overall product range for inhaled asthma and chronic respiratory disease medicines in the US. In addition, the presence of manual inhalers and lack of awareness about smart inhalers may impede its adoption which in turn restrict the market growth.
Despite the challenges, the global smart inhalers market size will continue to grow at a substantial rate driven by the novel technological advancements and rising partnerships between industry leaders. It is important to highlight here that the key industrial leaders are focusing on the development of innovative features within smart inhalers such as advanced sensors and connectivity options that help in the collection of data and transmit to healthcare providers for making treatment decision. Furthermore, industry players are emphasizing the integration of artificial intelligence, big data analytics and machine learning for real time tracking of predictive insights. The integration of smart technology enables players engaged in intranasal and inhaled drug development to develop connected devices, which will support the healthcare providers to design treatment plans and optimize the dosage. In addition, several industrial players have taken various strategic initiatives followed by partnerships to drive innovations in this field. In October 2024, Modivcare and Tenovi entered into a collaboration for the delivery of cost-effective Hailie smart inhalers (developed by Adherium) to the patients.
The market size is valued at USD 1.53 billion in 2024 and is expected to reach USD 5.84 billion by 2035. Driven by the growing demand for advanced medical devices for dosage delivery such as smart inhalers, the market is expected to grow at a higher CAGR of 12.95% during the forecast period. Interestingly, the companies engaged in the development of digital health technologies are extensively focused on assessment of the platforms across various drug delivery devices (including connected inhalers). One such company, Huma received the USFDA clearance of Software as Medical devices (SaMD), a Class II medical device, in June 2023. This disease-agonistic SaMD platform has the capability to integrate with medical devices, such as smart inhalers, blood sugar and heart rate monitoring devices. With more amalgamation of the players across the MedTech industry, we anticipate a boom in the smart inhalers industry wherein the management and prevention of the chronic diseases is more regulated.
Examples of key companies engaged in the development and commercialization of smart inhalers (which have also been profiled in this market report; the complete list of companies is available in the full report) include 3M Company, AstraZeneca, Adherium, AptarGroup, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GlaxoSmithKline, Glenmark Pharmaceuticals, H&T Presspart, Mundipharma, Novartis, Opko Health, Philips Respironics, Propeller Health, Sensirion, Teva Pharmaceuticals and Vectura.
Several recent developments have taken place in the field of smart inhalers. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.